抗体药物偶联物 (ADC) 已被证明可有效治疗各种癌症，特别是在靶向人表皮生长因子受体 2 (HER2) 阳性乳腺癌方面表现出特异性。 3 期临床试验的最新进展拓宽了目前对 ADC（尤其是曲妥珠单抗 deruxtecan）在治疗其他表达 HER2 的恶性肿瘤方面的认识。这种知识的扩展导致美国食品和药物管理局批准曲妥珠单抗 deruxtecan 用于治疗 HER2 阳性和 HER2 低乳腺癌、HER2 阳性胃癌和 HER2 突变非小细胞肺癌。随着 ADC 在肿瘤学中的使用不断增加，医疗保健专业人员越来越担心与抗 HER2 ADC 治疗相关的间质性肺疾病或肺炎 (ILD/p) 发病率的上升。抗 HER2 ADC 的研究报告了不同的 ILD/p 死亡率。因此，为接受抗 HER2 ADC 治疗的患者制定 ILD/p 的诊断和管理指南至关重要。为此，召集了一个中国专家小组，制定了识别和管理接受抗 HER2 ADC 治疗的患者 ILD/p 的战略方法。本报告介绍了专家小组的意见和建议，旨在指导临床实践中抗 HER2 ADC 治疗引起的 ILD/p 的管理。© 2024 美国癌症协会。

Antibody-drug conjugates (ADCs) have demonstrated effectiveness in treating various cancers, particularly exhibiting specificity in targeting human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Recent advancements in phase 3 clinical trials have broadened current understanding of ADCs, especially trastuzumab deruxtecan, in treating other HER2-expressing malignancies. This expansion of knowledge has led to the US Food and Drug Administration's approval of trastuzumab deruxtecan for HER2-positive and HER2-low breast cancer, HER2-positive gastric cancer, and HER2-mutant nonsmall cell lung cancer. Concurrent with the increasing use of ADCs in oncology, there is growing concern among health care professionals regarding the rise in the incidence of interstitial lung disease or pneumonitis (ILD/p), which is associated with anti-HER2 ADC therapy. Studies on anti-HER2 ADCs have reported varying ILD/p mortality rates. Consequently, it is crucial to establish guidelines for the diagnosis and management of ILD/p in patients receiving anti-HER2 ADC therapy. To this end, a panel of Chinese experts was convened to formulate a strategic approach for the identification and management of ILD/p in patients treated with anti-HER2 ADC therapy. This report presents the expert panel's opinions and recommendations, which are intended to guide the management of ILD/p induced by anti-HER2 ADC therapy in clinical practice.© 2024 American Cancer Society.